Categories
BLOG

cannabis and lymphoma

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center

Affiliations

  • 1 Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, [email protected]
  • 2 Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 3 Lev Hasharon Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 4 Oncology Division, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • PMID: 30343297
  • DOI: 10.1159/000493567

Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center

  • Search in PubMed
  • Search in NLM Catalog
  • Add to Search

Authors

Affiliations

  • 1 Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, [email protected]
  • 2 Department of Hematology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 3 Lev Hasharon Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • 4 Oncology Division, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • PMID: 30343297
  • DOI: 10.1159/000493567

Abstract

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed questionnaires, for all consecutive adult HL patients treated at the Tel-Aviv Medical Center between June 2010 and November 2016. One-hundred and thirty-three patients met the inclusion criteria. The median age of the cohort was 37 years, 53% were male, 46% were diagnosed at an early stage, and 88% achieved a complete response to treatment. Fifty-one patients (38%) used medical cannabis. There were no significant differences in baseline characteristics between cannabis users and nonusers. Cannabis users reported improvement in pain, general well-being, appetite, and nausea in 94, 87, 82, and 79% of cases, respectively. Importantly, 81.5% reported a high overall efficacy of cannabis in relieving symptoms. AEs related to cannabis use itself were mild. Thus, medical cannabis use is prevalent in this HL cohort, and appears to be effective in ameliorating chemotherapy-related AEs.

Keywords: Cannabis; Chemotherapy-related adverse events; Hodgkin lymphoma.

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and ev …

Cannabis Research for Non-Hodgkin’s Lymphoma

Adult non-Hodgkin lymphoma is a disease in which malignant (cancer) cells form in the lymph system.

Non-Hodgkin lymphoma is a type of cancer that forms in the lymph system, which is part of the body’s immune system. The immune system protects the body from foreign substances, infection, and diseases. The lymph system is made up of the following lymphocytes: B lymphocytes, T lymphocytes, and Natural Killer Cells.

Non-Hodgkin lymphoma can begin in B lymphocytes, T lymphocytes, or natural killer cells. Lymphocytes can also be found in the blood and also collect in the lymph nodes, spleen, and thymus. — National Cancer Institute

Below is a Library of Cannabis Research Study for Non-Hodgkin’s Lymphoma.

Prospective Analysis of Safety and Efficacy of Medical Cannabis in Large Unselected Population of Patients with Cancer

Cannabinoids as Anticancer Drugs

Expression of Cannabinoid Receptors Type 1 and type 2 in Non-Hodgkin Lymphoma: Growth Inhibition by Receptor Activation

Cannabis Research Library

Over 1000 studies covering over 130 topics compiled for easy browsing.

Mission Statement: Rebrand Marijuana to Cannabis to facilitate the education of Cannabis (and to have fun)!

Disclaimer: Sativaisticated staff are not medical or legal professionals. All subjective writings are merely opinions.

SATIVAisticated © 2019 Cultivated by Harmon Marketing Co.

Library of Cannabis Research Studies for Non-Hodgkin's Lymphoma by SATIVAisticated: A collection of scientific research studies that focus on Cannabis, Cannabinoids and Endocannabinoid System and how they might affect Non-Hodgkin's Lymphoma.